Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Poxel SA

< Previous 1 2 Next >
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
From Poxel SA
Via Business Wire
Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading
From Poxel SA
Via Business Wire
Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
From Poxel SA
Via Business Wire
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
From POXEL SA
Via Business Wire
New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society
From POXEL SA
Via Business Wire
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
From Poxel SA
Via Business Wire
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
From Poxel SA
Via Business Wire
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
From Poxel SA
Via Business Wire
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast
From POXEL SA
Via Business Wire
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
From POXEL SA
Via Business Wire
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook
From POXEL SA
Via Business Wire
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million
From Poxel SA
Via Business Wire
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
From POXEL SA
Via Business Wire
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan
From Poxel SA
Via Business Wire
Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting
From Poxel SA
Via Business Wire
Poxel to Report Its 2023 Annual Results by the End of April 2024
From POXEL SA
Via Business Wire
Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update
From POXEL SA
Via Business Wire
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
From POXEL SA
Via Business Wire
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
From Poxel SA
Via Business Wire
Poxel, winner of the 2023 edition of the I-nov contest
From POXEL SA
Via Business Wire
Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
From Poxel SA
Via Business Wire
Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
From POXEL SA
Via Business Wire
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
From Poxel SA
Via Business Wire
Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
From Poxel SA
Via Business Wire
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
From POXEL SA
Via Business Wire
Poxel to Report its 2022 Full Year Results by the End of March 2023
From Poxel SA
Via Business Wire
Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
From Poxel SA
Via Business Wire
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
From POXEL SA
Via Business Wire
Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
From POXEL SA
Via Business Wire
Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
From POXEL SA
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS